Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Growth in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 12,000 shares, an increase of 300.0% from the March 31st total of 3,000 shares. Based on an average trading volume of 73,000 shares, the short-interest ratio is presently 0.2 days. Currently, 0.7% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC acquired a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned approximately 7.87% of Virax Biolabs Group at the end of the most recent reporting period. Institutional investors and hedge funds own 8.61% of the company’s stock.

Virax Biolabs Group Price Performance

Shares of VRAX stock opened at $0.70 on Friday. Virax Biolabs Group has a 1-year low of $0.61 and a 1-year high of $5.45. The firm has a fifty day moving average of $0.82 and a two-hundred day moving average of $1.46.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.